Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and

Csaba Siffel1,2, Matthew S Davids3, Colin Anderson-Smits1

  • 1Global Evidence and Outcomes, Data and Quantitative Sciences Institute, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.

Advances in Hematology
|December 29, 2025
PubMed

Insights

Patients with multiple myeloma and secondary immunodeficiency face higher infection risks. Immunoglobulin replacement therapy may indicate a more vulnerable patient group, highlighting the need for better understanding of secondary immunodeficiency burden.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Multiple myeloma (MM) patients with secondary immunodeficiency (SID) are prone to infections.
  • Disease progression and treatment toxicity exacerbate infection risks in MM patients.

Purpose of the Study:

  • To assess the infection burden in MM patients with and without SID.
  • To compare outcomes between MM patients with SID receiving immunoglobulin replacement therapy (IgRT) versus those not receiving it.

Main Methods:

  • Retrospective cohort study using anonymized US claims data (October 2015-March 2020).
  • Patients aged ≥18 years with MM were classified into SID and no-SID cohorts based on IgG levels, diagnosis codes, and major infections.
  • SID patients were further stratified into IgRT and no-IgRT groups.

Main Results:

  • The SID cohort had significantly higher rates of infections (58.9% vs. 31.3%), severe infections (29.8% vs. 10.6%), and infection-related hospitalizations (26.9% vs. 9.1%) compared to the no-SID cohort.
  • Bacterial infections were most common, particularly in the SID cohort (49.2%) and IgRT subgroup (70.4%).
  • Overall survival was shorter in the SID cohort (12.6 months) versus the no-SID cohort (14.7 months).

Conclusions:

  • MM patients with SID experience a substantially higher burden of infection and poorer survival.
  • The increased infection rate in SID patients receiving IgRT suggests this subgroup represents a more vulnerable population.
  • Improved understanding and management of SID are crucial for enhancing outcomes in multiple myeloma patients.

Related Concept Videos

Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...